Skip to Content

Androgen Receptor Pathway Inhibitors (ARPIs) Are Superior to Taxanes for Castrate-Resistant Metastatic Prostate Cancer

The first results from the ProBio study show that treatment with ARPI leads to longer PFS, but Henrik Grönberg predicts that there will be many larger publications and results from the study in the future.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top